Regorafenib

From bench to bedside in colorectal cancer

Safi Shahda, Muhammad Wasif Saif

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Colorectal cancer (CRC) remains the third cause of cancer-related mortality in the USA. Despite the advances in screening, many patients present with incurable metastatic disease. Chemotherapy forms the basis of treatment for patients with advanced disease. Angiogenesis is an important step in developing metastases and, therefore, blocking the VEGF pathway seems promising. The development of bevacizumab as a monoclonal antibody targeting the VEGF pathway improved progression-free survival and overall survival in the metastatic settings, with no improvement in disease-free or overall survival in the adjuvant settings. Small molecules such as tyrosine-kinase inhibitors have been long evaluated in metastatic CRC with disappointing results in improving outcome. Most recently, the CORRECT study has resulted in improved outcome in patients with metastatic CRC who were heavily pretreated when they received regorafenib.

Original languageEnglish (US)
Pages (from-to)243-248
Number of pages6
JournalExpert Review of Clinical Pharmacology
Volume6
Issue number3
DOIs
StatePublished - May 2013

Fingerprint

Colorectal Neoplasms
Vascular Endothelial Growth Factor A
Survival
Protein-Tyrosine Kinases
Disease-Free Survival
Monoclonal Antibodies
Neoplasm Metastasis
Drug Therapy
Mortality
regorafenib
Neoplasms
Therapeutics
Bevacizumab

Keywords

  • angiogenesis
  • colorectal cancer
  • regorafenib
  • targeted therapy
  • VEGF

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Regorafenib : From bench to bedside in colorectal cancer. / Shahda, Safi; Saif, Muhammad Wasif.

In: Expert Review of Clinical Pharmacology, Vol. 6, No. 3, 05.2013, p. 243-248.

Research output: Contribution to journalReview article

Shahda, Safi ; Saif, Muhammad Wasif. / Regorafenib : From bench to bedside in colorectal cancer. In: Expert Review of Clinical Pharmacology. 2013 ; Vol. 6, No. 3. pp. 243-248.
@article{5948f3a2b13d438d97b558aef9751d46,
title = "Regorafenib: From bench to bedside in colorectal cancer",
abstract = "Colorectal cancer (CRC) remains the third cause of cancer-related mortality in the USA. Despite the advances in screening, many patients present with incurable metastatic disease. Chemotherapy forms the basis of treatment for patients with advanced disease. Angiogenesis is an important step in developing metastases and, therefore, blocking the VEGF pathway seems promising. The development of bevacizumab as a monoclonal antibody targeting the VEGF pathway improved progression-free survival and overall survival in the metastatic settings, with no improvement in disease-free or overall survival in the adjuvant settings. Small molecules such as tyrosine-kinase inhibitors have been long evaluated in metastatic CRC with disappointing results in improving outcome. Most recently, the CORRECT study has resulted in improved outcome in patients with metastatic CRC who were heavily pretreated when they received regorafenib.",
keywords = "angiogenesis, colorectal cancer, regorafenib, targeted therapy, VEGF",
author = "Safi Shahda and Saif, {Muhammad Wasif}",
year = "2013",
month = "5",
doi = "10.1586/ecp.13.11",
language = "English (US)",
volume = "6",
pages = "243--248",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Regorafenib

T2 - From bench to bedside in colorectal cancer

AU - Shahda, Safi

AU - Saif, Muhammad Wasif

PY - 2013/5

Y1 - 2013/5

N2 - Colorectal cancer (CRC) remains the third cause of cancer-related mortality in the USA. Despite the advances in screening, many patients present with incurable metastatic disease. Chemotherapy forms the basis of treatment for patients with advanced disease. Angiogenesis is an important step in developing metastases and, therefore, blocking the VEGF pathway seems promising. The development of bevacizumab as a monoclonal antibody targeting the VEGF pathway improved progression-free survival and overall survival in the metastatic settings, with no improvement in disease-free or overall survival in the adjuvant settings. Small molecules such as tyrosine-kinase inhibitors have been long evaluated in metastatic CRC with disappointing results in improving outcome. Most recently, the CORRECT study has resulted in improved outcome in patients with metastatic CRC who were heavily pretreated when they received regorafenib.

AB - Colorectal cancer (CRC) remains the third cause of cancer-related mortality in the USA. Despite the advances in screening, many patients present with incurable metastatic disease. Chemotherapy forms the basis of treatment for patients with advanced disease. Angiogenesis is an important step in developing metastases and, therefore, blocking the VEGF pathway seems promising. The development of bevacizumab as a monoclonal antibody targeting the VEGF pathway improved progression-free survival and overall survival in the metastatic settings, with no improvement in disease-free or overall survival in the adjuvant settings. Small molecules such as tyrosine-kinase inhibitors have been long evaluated in metastatic CRC with disappointing results in improving outcome. Most recently, the CORRECT study has resulted in improved outcome in patients with metastatic CRC who were heavily pretreated when they received regorafenib.

KW - angiogenesis

KW - colorectal cancer

KW - regorafenib

KW - targeted therapy

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84877604650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877604650&partnerID=8YFLogxK

U2 - 10.1586/ecp.13.11

DO - 10.1586/ecp.13.11

M3 - Review article

VL - 6

SP - 243

EP - 248

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 3

ER -